NCT07375563 2026-01-29NB-NK-2026Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyPhase 3 Recruiting5 enrolled
NCT04385277 2025-10-27Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Children's Oncology GroupPhase 2 Active not recruiting41 enrolled 13 charts